PriceTargets.com logo

Bicycle Therapeutics - BCYC Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $51.36
  • Forecasted Upside: 141.48%
  • Number of Analysts: 13
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 11 Buy Ratings
  • 0 Strong Buy Ratings
$21.27 As of 03/31/2023 01:00 AM ET
▼ -0.5 (-2.30%)

This chart shows the closing price for BCYC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Bicycle Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BCYC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BCYC

Analyst Price Target is $51.36
▲ +141.48% Upside Potential
This price target is based on 13 analysts offering 12 month price targets for Bicycle Therapeutics in the last 3 months. The average price target is $51.36, with a high forecast of $74.00 and a low forecast of $30.00. The average price target represents a 141.48% upside from the last price of $21.27.

This chart shows the closing price for BCYC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 13 investment analysts is to buy stock in Bicycle Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/8/2021
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/6/2022
  • 0 strong buy ratings
  • 8 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
4/6/2022
  • 0 strong buy ratings
  • 8 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
7/5/2022
  • 0 strong buy ratings
  • 12 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
10/3/2022
  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
1/1/2023
  • 0 strong buy ratings
  • 11 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
3/2/2023
  • 0 strong buy ratings
  • 11 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
4/1/2023

Latest Recommendations

  • 0 strong buy ratings
  • 11 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/1/2023Needham & Company LLCLower TargetBuy$72.00 ➝ $67.00Low
3/1/2023HC WainwrightReiterated RatingBuy$57.00Low
2/28/2023EF Hutton Acquisition Co. IReiterated RatingBuy$55.00Low
2/27/2023Cantor FitzgeraldReiterated RatingOverweight$74.00Low
2/15/2023Needham & Company LLCReiterated RatingBuy$72.00Low
2/15/2023HC WainwrightReiterated RatingBuy$57.00Low
2/15/2023EF Hutton Acquisition Co. IReiterated RatingBuy$55.00Low
1/5/2023EF Hutton Acquisition Co. IInitiated CoverageBuy$55.00Low
11/10/2022Piper SandlerBoost Target$37.00 ➝ $48.00Low
11/9/2022JMP SecuritiesLower TargetMarket Outperform$70.00 ➝ $46.00Low
9/21/2022Cantor FitzgeraldReiterated RatingOverweightLow
9/12/2022Morgan StanleyLower TargetEqual Weight$60.00 ➝ $45.00Low
9/8/2022JMP SecuritiesReiterated RatingBuy$70.00Low
8/31/2022CowenInitiated CoverageOutperformLow
8/31/2022CowenInitiated CoverageOutperformLow
8/22/2022SVB LeerinkBoost TargetOutperform$48.00 ➝ $50.00Low
8/5/2022SVB LeerinkLower TargetOutperform$69.00 ➝ $48.00Low
8/5/2022HC WainwrightLower TargetBuy$65.00 ➝ $57.00Low
7/28/2022BarclaysInitiated CoverageOverweight$30.00Low
7/6/2022Canaccord Genuity GroupReiterated RatingBuy$60.00N/A
6/6/2022JMP SecuritiesReiterated RatingBuy$70.00Low
5/23/2022Piper SandlerLower TargetOverweight$76.00 ➝ $37.00Medium
4/13/2022B. RileyDowngradeBuy ➝ Neutral$62.00 ➝ $33.00Medium
4/12/2022Needham & Company LLCLower TargetBuy$85.00 ➝ $75.00High
4/7/2022Cantor FitzgeraldInitiated CoverageOverweight$100.00 ➝ $80.00High
4/1/2022Cantor FitzgeraldReiterated RatingOverweight$100.00 ➝ $80.00N/A
3/3/2022JMP SecuritiesLower TargetMarket Outperform$85.00 ➝ $70.00High
3/2/2022B. RileyLower Target$72.00 ➝ $62.00Low
2/14/2022Morgan StanleyInitiated CoverageEqual Weight$60.00High
12/17/2021SVB LeerinkInitiated CoverageOutperform$70.00High
12/9/2021Needham & Company LLCInitiated CoverageBuy$85.00Medium
10/14/2021JMP SecuritiesBoost TargetOutperform$53.00 ➝ $85.00High
10/8/2021B. RileyBoost TargetBuy$56.00 ➝ $72.00High
10/8/2021Piper SandlerBoost TargetOverweight$46.00 ➝ $76.00High
10/8/2021OppenheimerBoost TargetOutperform$47.00 ➝ $65.00High
10/8/2021HC WainwrightReiterated RatingPositive ➝ Buy$39.00 ➝ $65.00High
10/7/2021Roth CapitalBoost TargetPositive ➝ Buy$35.00 ➝ $65.00High
9/30/2021B. RileyInitiated CoverageBuy$56.00High
8/11/2021JMP SecuritiesReiterated RatingBuy$53.00Medium
7/13/2021Piper SandlerBoost TargetOverweight$39.00 ➝ $46.00High
5/11/2021OppenheimerBoost Target$38.00 ➝ $44.00Low
5/7/2021HC WainwrightBoost TargetBuy$31.00 ➝ $39.00Low
5/7/2021Piper SandlerBoost TargetOverweight$35.00 ➝ $39.00Low
4/20/2021JMP SecuritiesInitiated CoverageOutperform$53.00Medium
1/20/2021Cantor FitzgeraldBoost TargetOverweight$30.00 ➝ $58.00Medium
1/15/2021OppenheimerBoost TargetOutperform$27.00 ➝ $38.00High
1/15/2021HC WainwrightBoost TargetBuy$28.00 ➝ $31.00N/A
12/3/2020HC WainwrightReiterated RatingBuy$28.00High
10/12/2020Cantor FitzgeraldInitiated CoverageOverweight$30.00Low
9/22/2020OppenheimerReiterated RatingBuy$27.00High
8/6/2020HC WainwrightReiterated RatingBuy$25.00Low
7/21/2020OppenheimerReiterated RatingBuy$27.00High
6/24/2020OppenheimerReiterated RatingBuy$27.00Low
6/11/2020OppenheimerInitiated CoverageOutperform$27.00High
5/8/2020HC WainwrightReiterated RatingBuy$25.00High
4/17/2020HC WainwrightInitiated CoverageBuy$25.00Low
11/14/2019Roth CapitalInitiated CoverageBuy$17.00 ➝ $17.00High
9/11/2019The Goldman Sachs GroupUpgradeNeutral ➝ Buy$14.00High
6/17/2019Jefferies Financial GroupInitiated CoverageBuy$22.00Low
6/17/2019The Goldman Sachs GroupInitiated CoverageNeutralLow
6/17/2019Piper Jaffray CompaniesInitiated CoverageOverweight$20.00Low
(Data available from 4/1/2018 forward)

News Sentiment Rating

0.61 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 8 very positive mentions
  • 16 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
Mentions as of
9/3/2022
  • 6 very positive mentions
  • 15 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
10/3/2022
  • 3 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/2/2022
  • 9 very positive mentions
  • 11 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
12/2/2022
  • 11 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
1/1/2023
  • 21 very positive mentions
  • 46 positive mentions
  • 9 negative mentions
  • 2 very negative mentions
Mentions as of
1/31/2023
  • 18 very positive mentions
  • 38 positive mentions
  • 3 negative mentions
  • 2 very negative mentions
Mentions as of
3/2/2023
  • 3 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
4/1/2023

Current Sentiment

  • 3 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Bicycle Therapeutics logo
Bicycle Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development of a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. Its portfolio includes internal product candidates that are directed to oncology applications. The company was founded by Gregory Winter, John Tite, and Christian Heinis in 2009 and is headquartered in Cambridge, the United Kingdom.
Read More

Today's Range

Now: $21.27
Low: $21.00
High: $22.12

50 Day Range

MA: $24.07
Low: $20.02
High: $28.94

52 Week Range

Now: $21.27
Low: $12.08
High: $50.47

Volume

135,418 shs

Average Volume

412,096 shs

Market Capitalization

$453.26 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.77

Frequently Asked Questions

What sell-side analysts currently cover shares of Bicycle Therapeutics?

The following Wall Street analysts have issued reports on Bicycle Therapeutics in the last year: B. Riley, Barclays PLC, Canaccord Genuity Group Inc., Cantor Fitzgerald, Cowen Inc, Cowen Inc., EF Hutton Acquisition Co. I, HC Wainwright, JMP Securities, Morgan Stanley, Needham & Company LLC, Piper Sandler, SVB Leerink LLC, and TheStreet.
View the latest analyst ratings for BCYC.

What is the current price target for Bicycle Therapeutics?

11 Wall Street analysts have set twelve-month price targets for Bicycle Therapeutics in the last year. Their average twelve-month price target is $51.36, suggesting a possible upside of 141.5%. Cantor Fitzgerald has the highest price target set, predicting BCYC will reach $74.00 in the next twelve months. Barclays PLC has the lowest price target set, forecasting a price of $30.00 for Bicycle Therapeutics in the next year.
View the latest price targets for BCYC.

What is the current consensus analyst rating for Bicycle Therapeutics?

Bicycle Therapeutics currently has 2 hold ratings and 11 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BCYC will outperform the market and that investors should add to their positions of Bicycle Therapeutics.
View the latest ratings for BCYC.

What other companies compete with Bicycle Therapeutics?

Other companies that are similar to Bicycle Therapeutics include Entrada Therapeutics, 2seventy bio, Arbutus Biopharma, Aerovate Therapeutics and Evolus. Learn More about companies similar to Bicycle Therapeutics.

How do I contact Bicycle Therapeutics' investor relations team?

Bicycle Therapeutics' physical mailing address is B900 BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0, CB22 3AT. The company's listed phone number is 441223261503 and its investor relations email address is [email protected] The official website for Bicycle Therapeutics is www.bicycletherapeutics.com. Learn More about contacing Bicycle Therapeutics investor relations.